In a show of unity, the U.S. House of Representatives voted unanimously Monday night to pass a major legislative package designed to accelerate the development of treatments for pediatric cancer and rare diseases.
The legislation, titled the Mikaela Naylon Give Kids A Chance Act, aims to close the research gap between adult and pediatric healthcare. While adults often have access to cutting-edge drug combination therapies, these options frequently fail to reach children.
The bipartisan effort was spearheaded by Rep. Michael McCaul (R-Texas) alongside Rep. Gus Bilirakis (R-Fla.), with support from a coalition including Representatives Debbie Dingell (D-Mich.), Kathy Castor (D-Fla.), and Doris Matsui (D-Calif.).
READ: “Hero” Or “War Crime”? White House Defends Admiral Behind Deadly Caribbean ‘Double-Tap’
Closing the Treatment Gap
Data indicates that nearly 16,000 children in the United States are diagnosed with cancer annually. Furthermore, while children comprise roughly half of all patients living with rare diseases, treatment options specifically approved for pediatric use remain scarce compared to those available for adults.
To address this, the new legislation merges two existing initiatives: the Give Kids a Chance Act and the Creating Hope Reauthorization Act. The bill seeks to shift the market dynamics of drug development through two primary mechanisms:
- Incentivizing Research: It reauthorizes the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program. This system encourages pharmaceutical companies to develop treatments for less profitable rare pediatric diseases by awarding them a voucher. This voucher allows the company to expedite the FDA review process for a different, more profitable drug in the future. Since 2011, this program has spurred the creation of treatments for at least 39 different rare conditions.
- Combination Therapies: The bill authorizes the FDA to direct researchers to study combinations of cancer drugs in pediatric trials, rather than studying drugs in isolation. This mirrors successful strategies currently used in adult oncology.
Lawmakers Speak on Impact
Proponents of the bill emphasized that the legislation removes bureaucratic hurdles without increasing government spending.
“Today, we celebrate the House passage of this critical, bipartisan effort to give children battling cancer and rare diseases a real chance at life,” said Rep. Bilirakis. He noted that the bill focuses on “restoring essential programs” to ensure therapies reach the patients who need them most.
READ: Border Czar Tom Homan Unleashed: ‘If We Can’t Vet Them, They’re Going Home’
Rep. Castor highlighted the efficiency of the measure. “This bipartisan legislation eliminates unnecessary red tape, prioritizes life-saving pediatric therapies and re-energizes pediatric drug research at no additional cost to taxpayers,” she said.
For Rep. McCaul, the passage of the bill carries personal significance. As a founder of the Childhood Cancer Caucus, he described the vote as a “beacon of hope” for families.
“Losing some of these kids has been the hardest part of my career,” McCaul said. “But today, I’m encouraged because I know Mikaela’s legacy—and all of their legacies—will live on in this bill forever and help save countless lives.”
Looking Ahead
The legislation also includes provisions from Rep. Matsui’s RARE Act, which is designed to prevent companies from abusing “orphan drug” status to block competition. Matsui urged the Senate to take up the measure immediately.
“For the rare disease community, every single day matters,” Matsui said.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
